Democrats have won both chambers in the midterms but have no 60-vote filibuster-proof majority and no veto-proof supermajority. For financial regulation, that means -
-- The big action will be oversight, not legislation: hearings, document requests, possibly subpoenas. Targets include agency accountability, DOGE’s role in regulatory cuts, and the financial dealings of Trump’s inner circle.
-- More subpoenas: Rep. Robert Garcia, the top House Democrat on Oversight, put it in two words: “Lawyer Up.” The White House isn’t expected to cooperate, so requests may go to the private firms that did business with it.
-- Crypto oversight: it has far more congressional support than the last time Democrats ran the committees, but scrutiny is coming. Crypto-PAC-backed candidates mostly won, yet critic Sherrod Brown is returning to the Senate from Ohio, Senator Warren will head the Senate Banking Committee and Rep Maxine Waters will lead the House Finance Committee
-- AI and prediction markets are next. Look for hearings on AI in lending and investor disclosures. CFTC oversight of prediction markets will be challenged, though real change outside the courts looks unlikely in the next 2 years.
--Bottom line for firms: expect more scrutiny, more information requests, and a less predictable regulatory environment. #FinReg #Crypto #AI
Next to Delhi's most famous protest site sits a working 300-year-old observatory. Surprisingly , these stone instruments still works, accurate to within seconds, because one astrophysicist spent years fixing it — instrument by instrument. What was she?
A thread. 1/17
A team @Yale invented a fake patient and had him try to buy GLP-1 drugs on 49 different websites. 45 of them wrote him a prescription. A couple in under five minutes. 🧵
There have been a lot of allegations that under Makary FDA leaders overruled staff – something Makary denied. Now there are receipts. Acting CDER Director Michael Davis placed a memo [https://t.co/JKcmDM4SsI] in the record outlining how his predecessor, Tracy Beth Høeg, repeatedly overruled career staff to quash approval of an sBLA from Sanofi for Tzield teplizumab to delay progression of type 1 diabetes.
Davis’s memo calls into question the integrity of the commissioner’s national priority voucher (CNPV) process, highlighting how it empowered political appointees to overrule career staff without providing evidence or documentation to support decisions. Davis also contradicts former Commissioner Marty Makary’s assertion that drugs were selected for CNPVs based on nominations from review staff.
Much more at: https://t.co/NZ4NrbX7kC
i built a site that explores which books are most popular across the brooklyn public library system!
+ see what's most popular borough-wide or by select neighborhoods
+ compare book tastes across neighborhoods
+ see ratings on goodreads + NYT best sellers
https://t.co/w5EqkMaKXK